Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03060512 · ClinicalTrials.gov registry record · Phase 4
To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 276
- Enrollment target
NCT03060512 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 276 participants.
The verdict
NCT03060512, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 276 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether patients with opioid induced constipation prefer treatment with naloxegol (Movantik) or with Polyethylene Glycol 3350.
Interventions
- DRUG Polyethylene Glycol 3350
- DRUG Movantik
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 276 participants |
| Start Date | 2017-03-02 |
| Est. Completion | 2017-08-23 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03060512
The ClinicalTrials.gov registry entry for NCT03060512 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 276 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Polyethylene Glycol 3350 is the first listed.
NCT03060512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03060512 about?
NCT03060512 is a clinical study titled "To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation". The purpose of this study is to determine whether patients with opioid induced constipation prefer treatment with naloxegol (Movantik) or with Polyethylene Glycol 3350.
What is the current status of trial NCT03060512?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 276 participants. The study started on 2017-03-02. Estimated completion is 2017-08-23.
What interventions are being tested in trial NCT03060512?
The interventions under investigation include: Polyethylene Glycol 3350 (DRUG), Movantik (DRUG).
Who is sponsoring clinical trial NCT03060512?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.